1-(3-氟-2-甲氧基苯基)乙胺 | 1220040-08-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3-氟-2-甲氧基苯基)乙胺
• 英文名称: 1-(3-Fluoro-2-methoxy-phenyl)-ethylamine
• 英文别名: 1-(3-fluoro-2-methoxyphenyl)ethanamine
• CAS: 1220040-08-3
• 化学式: C₉H₁₂FNO
• 分子量: 169.2
• InChiKey: XKDDLSQQLGMSCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG<br/>[FR] MODULATEURS N-BIPHÉNYLMÉTHYLINDOLE DE PPARG
  申请人：KAMENECKA THEODORE MARK

  公开号：WO2012170554A1

  公开（公告）日：2012-12-13

  The invention provides molecular entities that bind with high affinity to PPARG (PPARƴ), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, prediabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.